CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with stage IB to IIIA non-small cell lung ...

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of ...

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials ...

BARCELONA, Spain —The final overall survival (OS) results from the FLAURA study have now firmly established osimertinib (Tagrisso, AstraZeneca) as front-line therapy in patients with epidermal growth ...

An updated analysis of the phase III ADAURA trial revealed a median disease-free survival (DFS) of 5.5 years for early-stage, EGFR-positive non-small cell lung cancer (NSCLC) patients who received ...

Osimertinib is available in the tablet form to be taken by mouth (orally) once a day with or without food. In case of difficulty in swallowing, disperse the tablet in a glass of 60 mL or 2 ounces of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...